New Treatment Modality for Epilepsy
I've been following the development of intranasal therapy of epilepsy for quite a few years. Finally, intranasal midazolam (Nayzilam) has received FDA approval for the treatment of cluster seizures (acute repetitive seizures) on May 20, 2019.
At this year's American Academy of Neurology meeting in Philadelphia, PA, I interviewed Ed Hogan, MD, who presented his research on intranasal diazepam for epilepsy. This preparation also looks promising for FDA approval.
Intranasal therapy for epilepsy is intended as an adjunct to daily medication, so it doesn't remove the daily burden of anti-seizure medication. However, the acute administration of an effective intranasal product may eliminate the need for some costly and inconvenient ER visits, which should help improve the quality of life for patients with uncontrolled cluster seizures.
Please check out my interview with Dr. Hogan here.